News By Tag
News By Location
Anthera Pharmaceuticals Inc Investor Investigation over Executive Pay announced
An investigation for Anthera Pharmaceuticals Inc investors over potential breaches of fiduciary duties was announced and long-term NASDAQ-ANTH stockholders should contact the Shareholders Foundation at email@example.com
Investors who are current long-term stockholders of shares of Anthera Pharmaceuticals Inc , have certain options and should contact the Shareholders Foundation at firstname.lastname@example.org or call +1(858) 779 - 1554.
The investigation by a law firm focuses on whether certain directors and officers of Anthera Pharmaceuticals Inc (harmed the company by agreeing to pay certain of Anthera Pharmaceuticals’
Anthera Pharmaceuticals Inc reported that its Net Loss increased from $12.20 million in 2009 to $95.33 million in 2011.
Shares of Anthera Pharmaceuticals Inc declined from as high as $8.28 per share in February 2012 to as low as $0.60 per share in November 2012.
The total compensation of certain top officials at Anthera Pharmaceuticals Inc increased significantly between 2009 and 2011. For instance, the President and CEO’s total compensation rose from over $369,000 in 2009 to over $1.48 million in 2011, the Chief Business Officer and CFO’s pay increased from over $264,000 in 2009 to over $943,000 in 2011, and the Chief Medical Officer’s total compensation increased from over $289,000 in 2009 to over $936,000 in 2011.
On January 24, 2013, NASDAQ-ANTH closed at $0.713 per share.
Those who are current long-term stockholders of Anthera Pharmaceuticals Inc shares have certain options and should contact the Shareholders Foundation at email@example.com or call +1(858) 779 - 1554.